How accurate are multi-cancer early detection blood tests like Galleri?

Multi-cancer early detection (MCED) tests like Galleri are an evolving area of medical technology. They work by detecting "cell-free DNA" (cfDNA) shed by tumors into the bloodstream.

Here is what is currently understood about their accuracy:

Sensitivity and Specificity

• Specificity (High): These tests are generally very good at specificity, meaning they have a low rate of "false positives." When the test indicates cancer is present, it is often correct.
• Sensitivity (Variable): Sensitivity refers to the test's ability to actually detect cancer when it is present. This is significantly higher for later-stage cancers but drops substantially for early-stage (Stage I) cancers. Because the goal of these tests is early detection, this gap remains a major area of clinical research.

Key Considerations

• Not a Replacement: Medical organizations currently stress that MCED tests are not replacements for standard, guideline-recommended cancer screenings (like mammograms, colonoscopies, or cervical cancer screenings). They are intended to be complementary—a tool to be used alongside standard care.
• Diagnostic Journey: If an MCED test returns a positive result, it identifies a "cancer signal." It does not provide a definitive diagnosis. The patient must then undergo extensive follow-up testing—such as imaging or biopsies—to confirm the location and type of cancer.
• Clinical Utility: Researchers are still studying whether these tests actually improve long-term outcomes, such as decreasing cancer-related mortality. While they can detect signals early, it is not yet fully clear if detecting every identified signal leads to better patient survival rates or if it leads to "over-diagnosis" (treating cancers that might not have become life-threatening).

Current Status

The Galleri test is available in some regions, often as a laboratory-developed test. However, it has not yet received full FDA approval as a definitive diagnostic tool; it is typically marketed as a screening aid. Major health organizations, including the American Cancer Society, generally advise that individuals speak with their doctors to weigh the specific benefits and risks based on their personal health history rather than using these tests as a standalone screening method.

If you are considering this test, it is best to discuss it with your primary care physician to see if it is appropriate for your specific risk profile. If you have a specific study or recent clinical trial result you are curious about, please let me know, and I can look into the latest information for you.